CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.74B, above the global median of $1.15B
- FinancialsAltman Z-Score 3.67: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.74BUSDvs all stocks (USD)
Revenue (TTM)
268.68MUSDvs all stocks (USD)
Profit Margin
-5.57%Beta
0.2550xvs all stocks
52-Week Change
25.81%vs all stocks
Market Capitalization
1.74BUSDvs all stocks (USD)
Enterprise Value
1.88BUSDvs all stocks (USD)
Forward P/E
16.77xPrice to Sales (TTM)
6.23xPrice to Book (MRQ)
58.29xEnterprise to Revenue
6.99xEnterprise to EBITDA
48.30xGross Margin
61.18%Profit Margin
-5.57%Operating Margin
-49.95%Return on Assets (TTM)
3.14%Return on Equity (TTM)
-35.43%Revenue (TTM)
268.68MUSDvs all stocks (USD)
Revenue per Share (TTM)
7.24USDUpdated Jul 19, 2026Quarterly Revenue Growth
-7.60%Gross Profit (TTM)
199.11MUSDvs all stocks (USD)
EBITDA (TTM)
50.24MUSDvs all stocks (USD)
Net Income (TTM)
-14.96MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-7.59%Operating Cash Flow (TTM)
15.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.05MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
-355.00KUSDFY2025 · Dec 31, 2025Revenue
272.30MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
67.93MUSDFY2025 · Dec 31, 2025Gross Profit
204.37MUSDFY2025 · Dec 31, 2025Operating Income
30.52MUSDvs all stocks (USD)
Pre-tax Income
-1.37MUSDFY2025 · Dec 31, 2025Income Tax Expense
3.77MUSDFY2025 · Dec 31, 2025Net Income
-5.14MUSDFY2025 · Dec 31, 2025EBIT
22.81MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
50.24MUSDFY2025 · Dec 31, 2025Research & Development
20.94MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
152.91MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
24.18MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.1400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.1400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
36.76MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
36.76MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-5.14MUSDFY2025 · Dec 31, 2025Operating Cash Flow
29.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
28.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
72.93MUSDFY2025 · Dec 31, 2025Income Tax Paid
93.00KUSDFY2025 · Dec 31, 2025Interest Paid
18.72MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-5.14MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
19.68MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.05MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
5.01MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-4.61MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.08MUSDFY2025 · Dec 31, 2025Capital Expenditures
-887.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-215.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
-4.36MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
244.38MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-230.90MUSDFY2025 · Dec 31, 2025Other Financing Charges
-26.66MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-13.19MUSDFY2025 · Dec 31, 2025Shares Outstanding
37.27MSharesUpdated Jul 19, 2026Float Shares
28.28MSharesUpdated Jul 19, 2026Shares Short
7.15MSharesUpdated Jul 19, 2026Short Ratio
8.52daysvs all stocks
Short % of Shares Outstanding
21.35%vs all stocks
% Held by Insiders
15.47%vs all stocks
% Held by Institutions
58.86%vs all stocks
Total Cash (MRQ)
95.97MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.58USDUpdated Jul 19, 2026Total Debt (MRQ)
300.67MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
10.61xCurrent Ratio (MRQ)
2.48xBook Value per Share (MRQ)
0.7700USDUpdated Jul 19, 2026Total Assets
399.48MUSDvs all stocks (USD)
Total Current Assets
211.75MUSDFY2025 · Dec 31, 2025Total Liabilities
347.39MUSDFY2025 · Dec 31, 2025Total Non-current Assets
187.73MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
251.09MUSDFY2025 · Dec 31, 2025Total Current Liabilities
96.30MUSDFY2025 · Dec 31, 2025Cash
72.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
72.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
110.89MUSDFY2025 · Dec 31, 2025Inventory
13.52MUSDFY2025 · Dec 31, 2025Accounts Payable
35.35MUSDFY2025 · Dec 31, 2025Short-term Debt
887.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
788.00KUSDFY2025 · Dec 31, 2025Long-term Debt
251.09MUSDFY2025 · Dec 31, 2025Common Stock (Book)
37.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-156.52MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
52.09MUSDvs all stocks (USD)
52-Week Low
28.54USDUpdated Jul 19, 202652-Week High
54.85USDUpdated Jul 19, 202652-Week Change
25.81%vs all stocks
Beta
0.2550xvs all stocks
50-Day MA
37.92USDUpdated Jul 19, 2026200-Day MA
41.25USDUpdated Jul 19, 2026Avg 10-Day Volume
574.42KSharesUpdated Jul 19, 2026Avg 30-Day Volume
762.83KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.3800USDUpdated Jul 19, 2026Other Income / Expense
-7.70MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.61Profit Margin: -0.06
Financial Health
Altman Z-Score 3.67: safe zoneNotable
Altman Z-Score: 3.67
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.74B, above the global median of $1.15BNotable
Market cap (USD): 1,738,883,741Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Shyndec Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Precigen Inc.
Tier 1ProductionApproval-Gated PipelineRule